Treatment, Monitoring, and Management of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: Evidence From a Multi-Country Needs Assessment
This study aimed to establish the current knowledge, skills and confidence levels of oncologists, hematologists and hematologist‑oncologists (ONC/HEM) and identify the challenges they experience when managing and monitoring treatment and engaging patients with CLL or MCL in shared decision‑making.
This study aimed to establish the current knowledge, skills and confidence levels of oncologists, hematologists and hematologist-oncologists (ONC/HEM) and identify the challenges they experience when managing and monitoring treatment and engaging patients with CLL or MCL in shared decision-making. The long-term aim is to inform evidence-based continuing medical education to optimize ONC/HEM competencies.
The study sheds light on gaps in oncology professional knowledge and skills around new therapeutic options for patients experiencing relapse or refractory forms of chronic lymphocytic leukemia and mantle cell lymphoma, informing targeted education and quality‑improvement interventions in clinical practice.
Bizonyítékszint: Feltételezés / hírjelzés. Nincs önálló tudományos bizonyíték.
Kapcsolódó jelek
- Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice
- Milestones in Chronic Lymphocytic Leukemia
- Trial Results Show Majority of Patients With CLL Achieve uMRD With VenO
- On the architecture of translational research designed to control chronic lymphocytic leukemia
- Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)